BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY3962681 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY3962681\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06565195-1700@assetmemo.bio
DTSTAMP:20261121T005836Z
DTSTART;VALUE=DATE:20300723
DTEND;VALUE=DATE:20300724
SUMMARY:LY3962681: Phase 1 readout est. (NCT06565195)
DESCRIPTION:LY3962681\, phase 1\, Parkinson's Disease.\nStudy: A Clinical T
 rial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's D
 isease\nEstimated primary completion: 23 July 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ly3962681#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06565195
URL:https://assetmemo.bio/drug/ly3962681#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
